Bremelanotide Induces Cell Death in Aggressive Brain Cancer Cells
Background
Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults, characterized by rapid growth and high resistance to conventional therapies. Despite advances, the prognosis for patients with GBM remains poor, with a median survival of only 15-20 months. Current treatments often fail due to the tumor's invasive nature and the blood-brain barrier. This study investigates the potential of bremelanotide, a melanocortin receptor agonist, as a novel therapeutic agent against glioblastoma cells.
Results
The study found that bremelanotide significantly inhibited the growth and induced cell death in both U87MG and T98G glioblastoma cell lines in a dose- and time-dependent manner. At 10 µM, bremelanotide reduced cell viability by 48% in U87MG cells and 43% in T98G cells after 72 hours compared to untreated controls (p<0.01). Apoptosis was markedly increased, with a 3.2-fold increase in caspase-3/7 activity observed at 5 µM bremelanotide after 48 hours. Cell proliferation was also significantly suppressed, showing a 55% reduction at 10 µM bremelanotide compared to controls. > The most compelling finding was that bremelanotide induced substantial apoptosis and growth inhibition in glioblastoma cells, with a 60% decrease in cell viability at its highest concentration, suggesting a potent anti-cancer effect.
Why It Matters
This research highlights bremelanotide's potential as a novel therapeutic candidate for glioblastoma, a highly aggressive and treatment-resistant brain cancer. Given its known safety profile from other clinical applications, repurposing bremelanotide could accelerate the development of new treatments for patients with limited options. Future steps include validating these findings in more complex 3D cell culture models and in vivo animal studies to assess efficacy and safety in a living organism, potentially paving the way for Phase I human trials.